Literature DB >> 2972102

Effects of long term GnRH analogue treatment on hormone levels and spermatogenesis in patients with carcinoma of the prostate.

G Lunglmayr1, E Girsch, E M Meixner, G Viehberger, C Bieglmayer.   

Abstract

The effects of long term GnRH treatment with the biodegradable depot formulation of ICI 118.630 on hormone levels and spermatogenesis were investigated in 18 males with advanced prostate cancer. Plasma levels of FSH, LH, testosterone, DHEA-S and SHBG were monitored at regular intervals. The drug suppressed FSH, LH and testosterone significantly and did not affect DHEA-S and SHBG plasma levels. Tissue specimens for histologic assessment and quantitative analysis of germinal cell types were obtained at secondary orchidectomy in 16 patients immediately following GnRH analogue treatment. Germinal cell maturation was arrested at the spermatogonial stage. In two patients discontinuing treatment histologic assessment of secondary orchidectomy specimens 9 and 10 months after the last GnRH analogue depot injection resulted in germinal cell maturation to late spermatids in part of the tubule cross sections. These results indicate that long term administration of the GnRH analogue fails to produce complete testicular sclerosis and spermatogenic arrest might be reversible.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2972102     DOI: 10.1007/bf00263642

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  16 in total

1.  RAPID TOLUIDINE BLUE STAINING OF EPON-EMBEDDED AND MOUNTED "ADJACENT" SECTIONS.

Authors:  J A LYNN
Journal:  Am J Clin Pathol       Date:  1965-07       Impact factor: 2.493

2.  An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.

Authors:  M R Robinson; L Denis; C Mahler; K Walker; R Stitch; G Lunglmayr
Journal:  Eur J Surg Oncol       Date:  1985-06       Impact factor: 4.424

3.  The relationship between germinal cells and serum FSH levels in males with infertility.

Authors:  D M de Kretser; H G Burger; B Hudson
Journal:  J Clin Endocrinol Metab       Date:  1974-05       Impact factor: 5.958

4.  Testicular histology after prolonged treatment with a gonadotropin-releasing hormone analogue.

Authors:  J A Smith; R L Urry
Journal:  J Urol       Date:  1985-04       Impact factor: 7.450

5.  Androgen suppression by a gonadotropin releasing hormone analogue in patients with metastatic carcinoma of the prostate.

Authors:  J A Smith
Journal:  J Urol       Date:  1984-06       Impact factor: 7.450

6.  Testicular histology following chronic gonadotropin-releasing hormone agonist treatment.

Authors:  J Rajfer; R S Swerdloff; D M Heber
Journal:  Fertil Steril       Date:  1984-11       Impact factor: 7.329

7.  Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.

Authors:  G Tolis; D Ackman; A Stellos; A Mehta; F Labrie; A T Fazekas; A M Comaru-Schally; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

8.  [Spermatogenesis in the aged--a borderland between normal and pathologic anatomy].

Authors:  A F Holstein
Journal:  Urologe A       Date:  1986-05       Impact factor: 0.639

9.  Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex).

Authors:  K J Walker; A O Turkes; A Turkes; R Zwink; C Beacock; A C Buck; W B Peeling; K Griffiths
Journal:  J Endocrinol       Date:  1984-11       Impact factor: 4.286

10.  Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.

Authors:  S R Ahmed; J Grant; S M Shalet; A Howell; S D Chowdhury; T Weatherson; N J Blacklock
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-19
View more
  3 in total

Review 1.  Fertility preservation options in transgender people: A review.

Authors:  Natnita Mattawanon; Jessica B Spencer; David A Schirmer; Vin Tangpricha
Journal:  Rev Endocr Metab Disord       Date:  2018-09       Impact factor: 6.514

Review 2.  Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer.

Authors:  R N Brogden; D Faulds
Journal:  Drugs Aging       Date:  1995-04       Impact factor: 3.923

3.  Controversies in the management of advanced prostate cancer.

Authors:  C J Tyrrell
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.